ASAPF - Earnings call transcript Q4 2021 | Aurora Spine Corporation

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Good morning, and welcome to the Aurora Spine Reports Fourth Quarter and Fiscal Year 2021 Financial Results Call. All participants will be in listen only mode. [Operator Instructions] Please note this event is being recorded. I would now like to turn the conference over to Adam Lowensteiner with Lytham Partners.

You may now go ahead.

Adam Lowensteiner

quarter good today and results to Spine the and for you for Anthony, December for us ended joining review fourth you, morning, thank everyone, all Aurora XX, Thank XXXX. year and the financial company Spine. the and Northcutt, Aurora and the of Financial Chief are, Chad Trent With us Clouse, representing Officer today on Spine; call President CEO of Aurora

are as statements should, the the considered are or like are performance and intend, guarantees absence begin, factors performance remind Securities does and different achievements could, everyone XXXX, within during anticipate that and I other forward-looking future actual statements identify made projected. expect, These maybe statements, is expressions to from that call would of statement are to of current risks of Act subject of course I These a important could Section to believe, XXA this events expectations similar and not Before statements but cause of Act such the Section the concerning words forward-looking meaning material will, forward-looking. statements results be that and not reflect those XXXX. XX(e) not their and Securities to of uncertainties used amended future as may, of mean words,

the a Principles filed update Spine’s may regarding income of to as statements, On not EBITDAC, not I'd GAAP EPS, otherwise. are addition measures information Regulation similarly these and Investors comparable directly reports refer Accounting on call not or under intend with periodic over SEDAR, G reconciliation to should does to measures the performance supplemental file or net For these recognize measures accordance any EBITDAC, Trent, in new a A the a of set turn in adjusted company's or hear any Chief GAAP. and result Factors Management future to provide Executive the these full substitute to to that to that now Northcutt, information, most in on companies, or section. SEC of and discussion revise meaningful Mr. measures Trent, forward-looking in of non-GAAP found performance comparable measures to for prepared figures of other and we these Risk accordance the risks, might operational documents Accepted the Spine encouraged Aurora believes read superior that, including GAAP uncertainties addition titled as Spine. should you please be can not measure this with you. of figures performance. President with which other like non-GAAP Generally in adjusted in of and company's Officer forward-looking measures adjusted to earnings. can't factors, financial call, events non-GAAP management considered proceed. be whether to With Aurora Aurora Trent be mute, GAAP. are you're forth statements those under

Trent Northcutt

Thank status and the the that. some with the Spine our each call, us of on conduct like the of end. recap results. overview call. this new commentary the release result of started it you, our the I’d me our a be on Investor financial to Key and out review can us. issued well we today's numbers. websites. And today, at initiatives everyone a of results, and have Aurora about Chad a brief our new Earlier spine.com quarter, like that's of aurora-spine.com, aurora, join XXXX the hyphen, the produced summarize our of clinical news. a overall Relations welcome market our the behind SiLO then experience CFO, the our division, sorry, Clouse, demonstrated copy agenda product I'd session Adam. of found events press a a financial not, we bit website to the our To quarter few let will was. as go the key to then now as section other our and about QX, study, in conference quarter the Q&A fourth or I'd products under to a the our first like lay ZIP, key at and including on to products, events will initiatives including you've results But, I everyone dynamics Yes, fourth me detailing financial in COVID-XX and a appreciate and DEXA chance that financial had talk Sorry. Excuse today, to Hopefully, solid if line. issuance

other improvement actually While Aurora a there didn't some of business pre-COVID companies level the industry. our overall, our industry pockets sequential revenue as showed from experience in of and are there, cancellations as the the growth third surpassed still quarter. well levels quarter like little And bit in surgery here slowdowns significant and the of any year-over-year

slow the momentum addition, a has start. In fiscal off to solid XXXX gained and while starting

going what's on? a is unfolding So in multitude. phenomenon of The front believe we that us

were loving coming patients to fashion, serve to also that outcomes those at surgery saw day. doctors manner shown new boom the in improved invasive are protocol. home patients of out business. office. pandemic. health found the Doctors the in office, them the actually back shifted the done timely the their come coming the also or a confident to especially pursue this the return We people their First on concluding office in of doctors who minimally doctor's to In procedures, issues feeling center centers has back technology, COVID, their focused patient in and big own the in pandemic fact, in more either a in care towards Also and taking we they propose postponed Many of the a more and patients. of enable adopted health but into same because surgery

this management These practices. market, is in opioid the are doctors can sizable pain included and treat very that doctors that Two interventional are to evolve also of emergency a the their effective, continued incorporating be proprietary catalyst manner the into helps crisis continues looking for. devices in mindful need doctors and medications. the are invasive of as minimally patients manner Aurora's which Another pain Zip the are using what products, in highly addictive without exactly SiLO, pain a

lab During over and XXX and doctors XX traded proprietary allows we -- XXXX learn the aggressive program and or more goal in continue in and on than especially United on products to diligently trained created and scheduled the XXX focusing than way on doctor that various in did meeting doctors more cadaver on cities training well and year, and this our for XXXX. which are more to matter, doctors, States and We past the we of the an products for XX we're quarter what done the We Zip that have doctors doctors double year XXXX, should our SiLO. this Aurora's XXX the basically were me, -- education trainings, throughout through excuse to to focus fiscal on about year.

attracted new now new incorporated for incorporated for embraced practice surgery procedures trial practice. doctor the has device, on ZIP, our into many and utilize the and study that and hospital to which device their very doctors this We in also a join embarked many is or different well particular going clinical have center

device a ahead. Our contributor Joint has and it recently, has SI very believe a been key we positive future

to educate are continuing Joint to adopted by be SI doctors procedure continues SiLO. we the doctors, the As on

minimally direction non-allograft and unique We designed device a are approach, plan very controlled is called or has precision in to about into where very excited SI the concern. for surgery Joint SiLO-TFX. area our instantly us. made and reducing leave a is can relief the version is pain same the in that placed into patient next-generation again, joint center for is and the device, out that step have doctor of our about the we and and titanium of the been version device have that the invasive allow the will the this This which walk non-bone this will quarter the surgery center. exciting be – DEXA actually and give This and day the and right day, joint platform. actually walk the specifically advanced this a during be SI SI patient it is Other opioid What's instruments implant can technology

the running, We our creating Technology clearance and the have DEXA-C healing. that order superior during patient's a quicker ground Cervical product of of series implants, us bone patent very This patent obtained help third secured DEXA called We would a in hit by a to T-Score. key in allows employ and implant create bone promote densities to quarter. help was we the density DEXA growth that bone last FDA match the a technology to DEXA fixation patent in year, manufacturing,

now implants is this through positive are are how of your works some their or perfect has fact a surgery DEXA placed These that the is the right it made what focused patient are in sure that bone healthy Technology that company dialogue it practice. towards patient's a traction to if a building the device for performance and clinical and true made bone initial through for that summary specifically into working the We doctors a initial how have perfect that patient measurable cervical, based is that very within to The non-healthy density, this our of To procedure, not and staying What's to I'm body, patients and an outcome actually patient score gives company. product have the marketing implants patient's team the the this aspect density help upon to implants unique extremely about don't make doctor incorporate Spine, that doctor. that the conduct to year. in this surgeries measurement same and in in had that, recovery your actually procedures for some proud and variants all, in selected that joint density. a bone. performance most, other patient, product earlier on and had but into that The summarize, DEXA-C results smoothly, with a with the works was, all patients and we've patient's believe is actually We your gone is, are this lumbar patient. starting their manufactured

new take through positioned our well to clinical remain advantage penetrating these of markets year trials that will markets and several ongoing. training, this also growth continued are the succession and of key are proprietary result further products We on focused

is news are technologies positioned is proving to returned studies more focused product. Looking clinical well more that, and the and their Surgeries and behind to pandemic Aurora our products as the doctors for us. patients improving out have new teaching the Good health we longer-term, success, especially and use well-being. are on mostly

call our now the over financial please review Clouse, Spine. will proceed. Aurora the will CFO at He We results. Chad turn Chad, fourth to quarter

Chad Clouse

Thank you, Trent.

fourth and compared highlighted Revenue in fourth of XXXX. or products, of quarters expenses part during numbers comments more sequential million, detail from year invest the let in trials. profit and our our of beyond the in as of of in of on of XX% products. continued basis marketing the to the fourth improvement Total sales $X.X The This in products levels anticipate quarter proprietary Margins XXXX capability the XX.X% or more $X.X in training me in profit $X.X a million in Gross to revenue $X.X third fourth in of million million, remain usage focus coming showed million, the larger and revenue. the were in revenue. increase approximately XX% XXXX. a these was XXXX and portion the progress fourth XXXX the to in clinical Sales gross more of range Proprietary devices. areas. as operating sequentially improvement should have to products revenue $X.X With revenue. quarter. ago and by total Proprietary a the due higher quarter XXXX, expenses of or these driven especially, in ZIP levels, an proprietary was the of continued increase the million compared in building to of and quarter are million the expansion XX% press of are to Investors were $X of my few and quarter conducting were margin third These the revenue in $X.X Gross XX.X% of company the in continues even million sessions initiatives. was continued quarter within especially quarter a as fourth the in compared strong $X.X investments SiLO revenue. become release, quarter of quarter approximately fourth

XXXX. negative in decrease quarter year-over-year put and diluted be we quarter $X.X will quarter of -- XXXX, depreciation, -- to or operating year. in expenses, stock per $X.XX and share million fourth the compared negative position these QX do basic earnings QX loss believe in diluted While and a the of the in there the accelerating per $X.X to million EBITDAC proper due share compared higher growth. EBITDAC $X.XX $X.X compensation negative and million to before loss was in interest, for investments higher company a a EBITDAC or was $X.X negative to will basic last compared XXXX XXXX of of in million fourth million tax in expenses was $X.XXX Net

the with their of sheet. in strengthened million. funds product balance its XXXX net to raise necessary utilizing enabled inventory to secure availability practice. a our The products fiscal balance have company These sheet ensure to to the $X.X surgeons of capital company during Turning fees the

labs add receivables, used quarter, fourth levels. end million million the spine the exited the we physicians $X.X training to have cash At both million, key in from third the in XXXX. capital quarter of fourth the more end and pain educate deduct from to quarter around also the the of same doctors. of quarter increase of the We cities the market $X.X US with various to large sales of We $X.X had an about more

and increased have always that in these strong current a collections, position collections usually the number. are days. important keeping is have continuing able our cash improve financially is we been in operating The investments capture are strong burn a continue system investments investments keep We confident to to in working demonstrates but this business even in we -- burn while we'll to place the This making XX expenses. our in and very these limited and

to mature, As XXXX. conversation putting these profitability path experience on now we to the the improvements, back investments Trent. in turn I solid expect company company the to growth fiscal the

Trent Northcutt

Thank you, Chad.

from I'd as we like to company we it pandemic open more we further questions, Before the call that booked. to and the believe the and conclude stabilized surgeries has improve to from that continue should away get

to the that are been very We opportunities company spine and make in captures that have in busy the making pain expenditures evolving sure necessary the markets.

instrument new sales hires kits, these some new of and Some sets initiatives include building inventory, improve our and efforts. additional and to key licensing making

we So XXXX. efforts very far, excited and are the investments of progress are the in about happy company's these with

And and ready in medical said, confident Given growth. our innovative questions. as substantial an company, unique shareholder share our situation, device to opportunity answer very remain any very long-term value we is operator with create our that to

Operator

the begin now will session. We Instructions] question-and-answer [Operator

Trent Northcutt

I them my dazzled with presentation.

asking they to questions. I a know are few So, eager

Operator

Tom from with will question Microcap first Our come Instructions] [indiscernible] [Operator Connection.

go You ahead. may now

Unidentified Analyst

color that's for guys the with on I XXXX. XXX assume Love XXX the And the with we a taken have so training uptake on there year. doctors congratulations far some online doctor morning on to witnessed get this doctors quarter. training coming in number on been them LinkedIn. that of planned and place Good trained would

as same say evidence, be safe to rate can is is we expect last there the to So, XX%? of that the it adoption year

Trent Northcutt

last actually made And system. and SI inventory of were the We've did more the far And that XX% well. California introduced have and question. in training some to as on some Joint good study that you protocols tweaks, the Northern year, last Good SiLO quite The training updates adoption instruments. programs instrumentation also have to yes, will on and the if year help this only strong to the Dallas programs. Yes. quite the courses some we've improve will, introducing performance the year as ZIP those from introducing believe improved cadaver done and to kick-off I in doctors, have this with we we up of

Unidentified Analyst

can DEXA And at so were as month. me selling products XXXX, there wrong, taken products information understand per of doctors Perfect. averaging around $XX,XXX but I of doctors if Aurora the net, you the for off XX using end this correct the that I've pain and I'm

the there's math the by be XXXX, because doctors could if XXX effect. XXXX we trained, of exit equates with at end to XXX Now, some point if bound theoretically, a delayed doctors there's

month. the assessment? So, Is even that Is count $XX,XXX the on per doing fair by XXX end that of goal XXXX, a doctors

Trent Northcutt

also The we've ZIP are them it. early that -- SiLO the these year, Yes. device is on last adoption fair. the mostly we early Very incorporated goal we into year, ZIP to get focused obviously, focused and from physicians But year, in -- then and -- coming the the were for get trained on were in device. rate the we to

down like they're ZIP if have a training. So, on an following we seen some basically, delve to will the see we'd look, device, use use and device ZIP SiLO if usage but we said, in they increase terrific, going the that ourselves. to the of We

direction steps in also good right yes, and So a question. the

Unidentified Analyst

growth, doctors to doctors, a Perfect. devices to that see you of growing doctor. devices got Because a is per spent And source it's And SiLO to per right? devices that month increase of ZIP X.X doctor? very X.X to their see month average revenue that to got sold and follow up, per jump the per you've you what the per month in three of to six a possible of devices your as be I the per and sold could equate the amount cost organic about that's three your on help this you Organically $XX,XXX month? you increase, got that the So target, already, five for factor organic to see doing within organic growth selling just when devices? to to that it's to are sales doctors that

Trent Northcutt

of question from usage your last Ramey, joined direct It she year now technology Krissy into -- into yes. their and that through been Education, are upon interventionists. CRM is their certification each these we different train. up further directly an added to progress answer company. follow-up give a To all that's customers company, doing, neuro, course and a the interview What a since we of is our of they expand practice. coming was a that focus our have them pain one their Clinical we possible have question We and follows with based to spine this particular with we Director of The doctors orthopedic, training. adopt to how for They this year and our that and trainings our and these blended certified them as

pain a in amongst it's the neuro ortho, course, So course. talents Everything, and this collaboration of space. and in professions spine has

have PRIA doctor's country. payers release a preauthorization and in side and contract reimbursement. that to Healthcare, which see And So literature We things them or if all need is them. it's PRIA all of not with preauthorization. actually course. it's only the continue with them like just a it's And we've -- added neuro they'll a in mean, a their get patient front across where we the missing one that on press that. the works courses, in It's one if help are a we we large of I'm call things that the three. a Healthcare, company our they made we've small to the pain going touch CRM of a to piece on And seen it's all of is do and players, with today on what to follow I think the this the blend they

doctor into up -- when So when they those centerm knows that we gets pre-approved. go surgery the morning, all have in know been go the it's cases

Unidentified Analyst

of that Is already? is evidence -- have has that you it shown? have approval? rate seen -- And Perfect. getting a you next that Because question. What the was how witnessed the it my it's success doctor improved actually

Trent Northcutt

year, we to that see I add more to add like We've the our already to but -- already. measures these second the witnessed got knew see of be are we've start and that in we in doctors to because courses. the on it. little pre-authorizations that want year the running slower, own it, do metrics PRIA and in I'd a But of half the trained that bit for we'll that what yes, of it and multiple of out

start. So yes, it's off to a good

Unidentified Analyst

you are now? seeing success Where Perfect. right greatest Perfect. the

Trent Northcutt

The from in really fastest it's in been growth and increasing steady growth the the ZIP really is -- device. I well, guess, ZIP usage has is

that. last So the We with we're -- -- numbers because XX field had trays. year SiLO kits really little surgical instrument year, out kits only interesting you And we last We which pleased only out we lost only you that those by the we lost last have over are got came XX was in sets. the two them had the XX in year. imagine, in can mail, as the of of now very you've two field -- frustrating, XX had

at we the -- ordered inventory beginning actually sets. So we first to the more got quarter, more had of

we over actually rev instrument throughout kits of the push for kits XX XX us another have year SiLO. so would -- that So

my procedure this the or for SiLO to kits And that actually warehouse field So either team, a set conference my doctor really training the for a actively training in accounts we be with a on in the all when I on weekend, was really performed. at the are told availability. me had eyes office technology SiLO they

been So third increase a for that's alpha technology, sure. it's trial release, we mentioned -- series DEXA of as the DEXA-C although performed, was this nine with we have had be a I multicenter in system going case it the an beginning And presented a soon. its that from DEX review to really only this those and year had part and one technology, in from FDA a these neuro and university And Orthopedics had group weekend with all was the university of several Chief we doctors and nice patients XXX(k) of approved. is are these reviews cervical surgeons, have and review surgeons had we and there, surgeons, the ortho. nine We It's study just a surgeons and great roundtable of we're really this cleared. nine front how

Unidentified Analyst

DEXA you -- you and understand surgery when of And understand, spinal but use can a speaking, and used that lot not have along on cage in I many there that you on call people devices elaborate surgery. with this a generally are may

So how that it's other when it a DEXA, up comes are you or promote marketing just so Aurora do products, how trying DEXA to to you package your sale. in your other -- products not

sell might most price? device. you to try You at those Are are and other you possible. of to a Are the products? SiLO a you as capitalize offering devices doing package revenues the amount pushing gain What

Trent Northcutt

We've the cervical a DEXA Implant been cervical fusion in device. forward positioning anterior as leap

we've see way that because want quite So gone are listed list a have we facility above well. -- sites to the and this -- ran is cases now before these we're two had better -- cervical over they that right getting indeed a their for to actually we if price Xx cases over them particular is one treat

a what The sell second XXX%, Interbody had location Device premium for. our normally above we of

which press actually not had third-party third-party Cervical on good on we think all because can year on replacing touched that got But a we the this. Plate, the like our touching real with are products. So I that's the be that which everywhere. going that that we product XXX(k) APOLLO that, the out no packaging and encouraging the a I we've get we and sign. something evolved is on not that release do we from will Cervical fact be it Plate, which away necessarily -- to was a lands There's price is not put last do

we is the that in cage, the implant. makers DEXA the are company and a implant. So with biologics publicly And to use course, traded we and provides us, Biologics, national allograft a also they our DEXA agreement which of SiLO then, have of a Aziyo

going in. three of all products it's So those

the plate, cage, as the premium the getting and price we're with off So the biologic for good we a it. year started that

Unidentified Analyst

Nice. Nice.

don't look that say obtain is -- push, two DEXA, So… package at that tool, the I'm just or of one not Aurora three is I I at is to trying right? guess, the on guess, sale, is out to what obtain that's it marketing So look a just but because to potentially,

Trent Northcutt

is add is technology, something I The is either about do Echolight, a and is a -- you in and is DEXA density. Well, Osteopenia what's called yellow, this and simple the point few green I we osteoporosis. of the Echolight presence out within can patient patient bone should I in. there's it’s based and out, they being red co-marketing that into density really patient's the and scores density red, actually healthy, procedure the – the And know bone company an being It’s has right it entered color can know do stand also the -- it's T-score I'll the before the agreement and minutes, also that, measuring did and missed, pre-ops unique yellow a reading ultrasound device. fact, bone or clinic of a in upon a it's actually measure just with to patient's the in clinic it’s code. doctor doctor's it patients the bone a And green, then what density,

on Store. you DEXA-C our patient's you'll our they're value cages, see it's four So to look and there. color-coded. score value the say, will a score, course, within a a what upon to website, the that, a of cages, then, if from very And numeric system in They're numeric based the well, was plus T four, small that then each so between minus the close is doctor so

pre-select, doctors can put doctor time the the patients So This to is into to first this to they're and has available been the ever which implant going patient. ever.

an is, has patient has implant patient's bone. matching versus a suited else has and a the better product the only density and their one-size-fits-all, approach bone likelihood to which everyone So of having better for Aurora this proprietary

Unidentified Analyst

to an month, keep doctors breakeven, numbers, on And Yes. course, throughout to bound expenses to to stable $X.X is we will to are breakeven expenses the a should this eye rise. same the increase see rise. number million curious they What be more? even did expenses, as of I'm new now? is On the with that going that's going breakeven, the be to or trained new Amazing, told higher the looking is more Can expenses million What amazing. $X We're we at? expect training year, to forward?

Trent Northcutt

No.

know going of Some SiLO-TFX, the beginning into SI expenses to biomechanical our some right the needed the on of add-on the year in we for the that to of which the earlier, the joint collect into you a year end the We and came is related new data some of we that little so it increase budget, we more didn't FDA to that so question a was added I to And needed training. about submit more to experience biomechanical ask data the the in system. TFX that did cost.

biomechanic challenges -- this as the able a that year, little to of by that balance more build in kits so decided that were some COVID. to out, can on by came building getting we a the part testing listed we of specimen and last was use to of up up, collect will, data. than as imagine, R&D, of were And if was had couple We that could some that work inventories. towards money to originally there, you all you for harder One specimens a get was right? in we put also seasonal costs. was mechanical to having data, We So affected had down, not COVID, add-on scheduled, that everything and do and but expect some training the settle expediting you bit

Unidentified Analyst

got I you.

an it more million, going that we cost. so $X.X adjusting know realistic number? is assume million the that doctor million, or be brought I $X.X is should Just at for well breakeven obviously have increased there's just sales of to -- Should we breakeven? end $X forward, because better even on training to $X.X going be a number million look So ever still XXXX. as to to during slightly there's

Trent Northcutt

because say I fair million be of that yes. Yes, breakeven right around would would number, $X.X

Unidentified Analyst

Perfect. Okay.

that XX% be Would just see believe higher XX% you for be you meaning, QX than how better no that of again about growth will than that of on in grew mentioned sequentially QX, Well, release better. you press expectations sequential much? You and will growth that more sequential we mentioned better? year-over-year. your sequentially or QX the just terminology kind they QX, Is

Trent Northcutt

To is understand from talking the into where up do you're about QX, QX go we question, that…

Unidentified Analyst

Yes, exactly. sequential? read I How do

Trent Northcutt

Yes.

what this felt about to better way, the all QX. So second answer was harder end off did And even even QX, really be couldn't the because, right really running and We did in than of the hit felt kind of started of advanced we We more into year. pleased year we half like dive your forward, we last QX. we we springboarded ground year, the than really about of had last QX, good it I down. headwinds question of start And to really QX. but great

team tightened pleased the So got really these educator the meetings clinical really, with up. in how really executed, there, got

how especially going where we're here started we've already about So, QX, I'm in really encouraged QX.

Unidentified Analyst

you products. us doctors last now we year, have our through claimed give And could many might could QX doctors already they're that increased. had we LinkedIn any how doctors If selling seen XX I've that we new see -- on on Perfect. have indication that Perfect.

So in more. last at it's alone, I know four least or month the

it If we guess, QX see right? you you're path, are on XX doctors XXX XXX. we per has that potentially, of I right the results? a -- doctors shown -- training those Has gaining could XX, quarter, So, is

Trent Northcutt

in I can jump there.

devices, use different doctors had So XX just generic, QX, so… we our

Unidentified Analyst

Yes.

right on target. So that's

Trent Northcutt

Yes.

Unidentified Analyst

exactly perfect. That's looking was exactly numbers That's I the on Those target. are for.

Chad Clouse

– the also on keep in a cut have pending front me, the everyone the into the of approval thing FDA training TFX. with I other TFX is to don't not an a we're the strategy eye and second -- And already in place current are of on a program that's training but -- the we The year. educational to is, ball -- right that throughout I our device plan fit has obviously, can for

sets instrument we come-off and training approval machining, those right XXX(k) a the program. implement the gets into it second the So

we're that but think this budget it revenues. we for that really are accelerate can not So -- year, revenue in think we hit numbers we could the that

a even beyond larger growth XX%. So

Unidentified Analyst

Beautiful.

just have sell or no does both? SiLO – you will just will the SiLO will drop longer Now off, current you --

Trent Northcutt

We will maintain both.

Unidentified Analyst

okay. cool. Okay, Very

to platform point to we be series of maybe products? will something there future that expect some acquiring, at see the of As look for is can is newer a anything DEXA else at new – additions, be products announced or either Are that carried there in that you'll don't I know?

Trent Northcutt

you're DEXA also you'll from And the work we're there's the and that might DEXA The with to is platform -- say doubt platform, no well. with -- would see in technology. as then in to into expansion going in lumbar cervical space that some DEXA SI technology, the -- we're go the looking how there's out joint platform. on going I spot

major cover of and in especially for So, in doing the performance. patient's They very areas to bone have fusion unique all well us, we'd for the novel the three areas. three implant only we're us patient if have those sectors be world matched

Unidentified Analyst

Okay.

are is out on licensing for carried that that As DEXA, discussions is that something within…

Trent Northcutt

be and that on -- claims discussing discussed branching key the now in would this be and data in We we're And our on since no those plans roundtable implant total are something have study the I markets implants. a phone to total weekend. here, was they they can’t, so they added we discuss we market, from based this have calls getting - had manufacturing technology some They that started products with and to told we technology. printing me companies company office. Watershed, of a getting which DEXA were be the got XD that get that and our hip, support And other of might in do type able exploring. the as DEXA, could we to press upon bone think, factor with they that from the is, well there the we making And presenting some we those cervical to just sidebar show roundtable nine affect would to they releases want is out couple of those And give its interact then this the in surgeons clinical multicenter patent that to said, also is we are this steps license. the that And of had a that are dental you the them knee walking vendors think with who the the proprietary. people course, that saying, technology yes, how our hey,

to get hold You a Aurora. of need

So and we if to opportunity will. the that technology, yes, was see here We will. an license exciting. I we mean out interesting

Unidentified Analyst

questions guys, Well, hog I want Beautiful. don't the call. exhausted to my and I've

it So very, on time your I'll leave much thank for others. congratulations for you a But quarter. very great and

Trent Northcutt

you. Thank

Operator

closing like Thank question-and-answer you. concludes [Operator our Trent Instructions] Northcutt It the over to questions. back appears session. there are any conference to This I'd turn further remarks. no for

Trent Northcutt

we for beyond Well, in this questions, with and a get follow-up with to Lowensteiner very many you. chatting about to your us, so any your if you forward excited a to We a Spine. Feel XXXX reach Adam the day. -- to and look again and at the speaking to what's of forward year team, Aurora if schedule pleased interest thank have We're on you hold in and Really be ahead. of rest call weeks you with great any please you. happy the look and Have Lytham beyond you time he'd of out going to Partners, here questions XXXX. have free, results

Operator

concluded. today's presentation. now attending has conference for you Thank The

disconnect. You may now

Aurora Spine (ASAPF) 2 May 222021 Q4 Earnings call transcript